795 related articles for article (PubMed ID: 15378477)
1. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
2. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
5. Type and duration of exogenous hormone use affects breast cancer histology.
Kumar AS; Cureton E; Shim V; Sakata T; Moore DH; Benz CC; Esserman LJ; Hwang ES
Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262
[TBL] [Abstract][Full Text] [Related]
6. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status.
Bardia A; Hartmann LC; Vachon CM; Vierkant RA; Wang AH; Olson JE; Sellers TA; Cerhan JR
Arch Intern Med; 2006 Dec 11-25; 166(22):2478-83. PubMed ID: 17159013
[TBL] [Abstract][Full Text] [Related]
7. Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy.
Tewari M; Pradhan S; Singh U; Shukla HS
Breast; 2007 Oct; 16(5):540-5. PubMed ID: 17587581
[TBL] [Abstract][Full Text] [Related]
9. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
10. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
[TBL] [Abstract][Full Text] [Related]
11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Kumar AS; Benz CC; Shim V; Minami CA; Moore DH; Esserman LJ
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1028-33. PubMed ID: 18463402
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect between alcohol and estrogen replacement therapy on risk of breast cancer differs by estrogen/progesterone receptor status in the Iowa Women's Health Study.
Gapstur SM; Potter JD; Drinkard C; Folsom AR
Cancer Epidemiol Biomarkers Prev; 1995 Jun; 4(4):313-8. PubMed ID: 7655324
[TBL] [Abstract][Full Text] [Related]
14. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
16. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.
Keshgegian AA
Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626
[TBL] [Abstract][Full Text] [Related]
17. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
[TBL] [Abstract][Full Text] [Related]
18. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
19. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]